Board Meeting30 Apr 2026, 03:27 pm
Dr. Lal PathLabs: Q4/FY26 Results, ₹4 Dividend, Acquisition, Dubai WOS
AI Summary
Dr. Lal PathLabs' Board approved audited Q4/FY26 financial results and recommended a final dividend of ₹4 per equity share for the financial year ended March 31, 2026. The company also announced the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary, and the incorporation of a new wholly-owned subsidiary in Dubai, UAE. Additionally, the Board re-appointed Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as Independent Director, designated two Senior Management Personnel, and re-appointed internal and cost auditors. The company also allotted 82,750 equity shares under its Employee Stock Option Plan 2022.
Key Highlights
- Board approved audited Q4 and full-year FY26 standalone & consolidated financial results.
- Recommended a final dividend of ₹4 per equity share for FY26, record date June 26, 2026.
- Acquired 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a WOS.
- Approved incorporation of a new Wholly Owned Subsidiary in Dubai, UAE.
- Re-appointed Executive Chairman and an Independent Director for five years.